Four Factors to Inform the Future of Pharma Reshoring
During much of 2020, there have been calls to “onshore,” or “reshore” API (Active Pharmaceutical Ingredient) manufacturing to the United States. Supply chain gaps in capacity, both local and global, became more apparent, something that most industry experts and the FDA knew existed on some level. It was a normal fear and security response to…